See LEGEND for key to shading and symbols.
Subject Area - BABS Term - Term 2 2021
BABS1112 | BABS1202 | BABS2202 | BABS3031 | BABS3081 | BABS3291 |
BABS3301 | BABS3631 | BABS4516 | BABS5019 | BABS5029 | BABS5039 |
BABS7020 | BABS8010 | BABS8050 | BABS8100 |
Data is correct as at Tue 28 Sep 20:30:55 AEST 2021
Comp | Sect | Class | Type | Status | Enr/Cap | % Full | Times (weeks, Location) - default 1hour |
BABS1112 | Genetics and Society | ||||||
CRS | CR01 | 3455 | Open | 0/281 | 0% | (Course Enrolment, UGRD) | |
DST | DST1 | 10214 | Enr | Open | 21/300 | 7% | |
BABS1202 | Applied Biomolecular Sciences | ||||||
CRS | CR01 | 2650 | Open | 0/22 | 0% | (Course Enrolment, UGRD) | |
LAB | T10A | 3826 | Enr | Open | 41/42 | 98% | Tue 10-13 (w2-5,7-10, TchLab 10) |
LAB | T10B | 10360 | Enr | Open | 40/42 | 95% | Tue 10-13 (w2-5,7-10, TchLab 11) |
LAB | T14A | 3827 | Enr | Open | 34/42 | 81% | Tue 14-17 (w2-5,7-10, TchLab 10) |
LAB | W10A | 3828 | Enr | Open | 41/42 | 98% | Wed 10-13 (w2-5,7-10, TchLab 10) |
LAB | W14A | 3829 | Enr | Open | 36/42 | 86% | Wed 14-17 (w2-5,7-10, TchLab 10) |
LEC | M15A | 3825 | Rel | Open | 192/256 | 75% | Mon 15# (w1-2,4-5,7-10, Online); Thu 13# (w1-5,7-10, Online); Fri 14# (w1-5,7-10, Online) |
BABS2202 | Molecular Cell Biology 1 | ||||||
CRS | CR01 | 2662 | Open | 0/42 | 0% | (Course Enrolment, UGRD) | |
LAB | T10A | 6434 | Enr | Open | 44/55 | 80% | Tue 10-13 (w1-5,7-10, TchLab 12) |
LAB | T14A | 6435 | Enr | Open | 37/55 | 67% | Tue 14-17 (w1-5,7-10, TchLab 12) |
LAB | W10A | 6436 | Enr | Open | 45/55 | 82% | Wed 10-13 (w1-5,7-10, TchLab 12) |
LAB | W14A | 6437 | Enr | Open | 34/55 | 62% | Wed 14-17 (w1-5,7-10, TchLab 12) |
LEC | M13A | 6433 | Rel | Open | 160/220 | 73% | Mon 13# (w1-2,4-5,7-10, Online); Wed 13# (w1-5,7-10, Online); Fri 10# (w1-5,7-10, Online) |
TUT | F11A | 6432 | Rel | Open | 160/200 | 80% | Fri 11 (w1-5,7-10, Law Th G04) |
BABS3031 | Biotechnology & Bioengineering | ||||||
CRS | CR01 | 2548 | Open | 0/18 | 0% | (Course Enrolment, UGRD) | |
LAB | W10A | 6767 | Enr | Open | 35/37 [40] | 95% | Wed 10-13 (w1-5,7-10, TchLab 11) Comb/w BABS3631 |
LAB | W14A | 6768 | Enr | Open | 30/40 | 75% | Wed 14-17 (w1-5,7-10, TchLab 11) Comb/w BABS3631 |
LEC | A | 6766 | Rel | Open | 65/80 | 81% | Mon 09-11# (w1-2,4-5,7-10, Online); Tue 09# (w1-5,7-10, Online) Comb/w BABS3631 |
BABS3081 | Bacteria and Disease | ||||||
CRS | CR01 | 2599 | Open | 0/22 | 0% | (Course Enrolment, UGRD) | |
LAB | H14A | 4996 | Enr | Open | 21/64 | 33% | Thu 14-18 (w1-5,7-10, TchLab 12) |
LAB | H14B | 4997 | Enr | Open | 33/64 | 52% | Thu 14-18 (w1-5,7-10, TchLab 11) |
LEC | M14A | 4998 | Rel | Open | 54/75 | 72% | Mon 14# (w1-2,4-5,7-10, Online); Tue 12# (w1-5,7-10, Online); Fri 12# (w1-5,7-10, Online) |
BABS3291 | Genes, Genomes & Evolution | ||||||
CRS | CR01 | 2540 | Open | 0/28 | 0% | (Course Enrolment, UGRD) | |
LAB | W14A | 3786 | Enr | Open | 23/30 | 77% | Wed 14-18 (w1-5,7-10, Wurth 122) |
LAB | W14B | 3787 | Enr | Open | 5/30 | 17% | Wed 14-18 (w1-5,7-10, Wurth 123) |
LEC | M15A | 3785 | Rel | Open | 28/50 | 56% | Mon 15# (w1-2,4-5,7-10, Online); Wed 13# (w1-5,7-10, Online); Fri 13# (w1-5,7-10, Online) |
BABS3301 | Biochem Lab Project | ||||||
CRS | CR01 | 3081 | Open* | 0/12 | 0% | (Course Enrolment, UGRD) | |
PRJ | PRJ1 | 9825 | Enr | Open* | 3/15 | 20% | |
BABS3631 | Biotech Bioeng (Adv) | ||||||
CRS | CR01 | 2562 | Open* | 0/2 | 0% | (Course Enrolment, UGRD) | |
LAB | W10A | 6770 | Enr | Open* | 12/14 [18] | 86% | Wed 10-13 (w1-5,7-10, TchLab 11) Comb/w BABS3031 |
LAB | W14A | 6771 | Enr | Open* | 4/18 | 22% | Wed 14-17 (w1-5,7-10, TchLab 11) Comb/w BABS3031 |
LEC | A | 6769 | Rel | Open* | 16/18 | 89% | Mon 09-11# (w1-2,4-5,7-10, Online); Tue 09# (w1-5,7-10, Online) Comb/w BABS3031 |
BABS4516 | Biotech and Biomolecular Hons | ||||||
CRS | CR01 | 2420 | Open | 0/19 | 0% | (Course Enrolment, UGRD) | |
PRJ | PRJ1 | 10074 | Enr | Open | 62/80 | 78% | |
BABS5019 | Research Project (6 UOC) | ||||||
CRS | CR01 | 1452 | Open | 0/3 | 0% | (Course Enrolment, PGRD) | |
OTH | OTH1 | 9992 | Enr | Open | 2/5 | 40% | |
BABS5029 | Research Project (12 UOC) | ||||||
CRS | CR01 | 1449 | Open | 0/4 | 0% | (Course Enrolment, PGRD) | |
OTH | OTH1 | 9993 | Enr | Open | 1/5 | 20% | |
BABS5039 | Research Project (18 UOC) | ||||||
CRS | CR01 | 1794 | Open | 0/5 | 0% | (Course Enrolment, PGRD) | |
BABS7020 | Biotech Comm Strategy | ||||||
CRS | CR01 | 1302 | Open | 0/0 | N/A | (Course Enrolment, PGRD) | |
DST | DST1 | 10173 | Enr | Closed | 0/100 | 0% | |
BABS8010 | Adv Topics in Biotech & Biomol | ||||||
CRS | CR01 | 1797 | Open* | 0/3 | 0% | (Course Enrolment, PGRD) | |
LEC | LEC1 | 9840 | Enr | Open* | 0/3 | 0% | |
BABS8050 | Research Thesis Part-Time | ||||||
CRS | CR01 | 3472 | Open | 0/9 | 0% | (Course Enrolment, RSCH) | |
THE | THE1 | 3489 | Enr | Open | 1/10 | 10% | |
BABS8100 | Research Thesis Full-Time | ||||||
CRS | CR01 | 3473 | Open | 0/8 | 0% | (Course Enrolment, RSCH) | |
THE | THE1 | 3488 | Enr | Open | 2/10 | 20% | |
^ top ^ | |||||||
LEGEND | |||||||
* This class requires consent. Students cannot self-enrol. | |||||||
# Timetable clash allowed. | |||||||
/odd Runs in odd weeks only. /even Runs in even weeks only. | |||||||
Comb/w Jointly taught with corresponding class(es) for specified course(s). Capacity shown is effective capacity. | |||||||
Effective capacity is the class capacity less any places taken by students in the other jointly-taught classes. | |||||||
[ ] Class capacity where different from effective capacity. | |||||||
Shaded cells: | LEC | Activity different from previous | |||||
Stop | Status is Stop Further Enrolment, Tentative, Closed or Cancelled | ||||||
100% | Class is full (> 100% means capacity is exceeded) | ||||||
80% | Class is nearly full (80% or more) | ||||||
50% | Class is half full | ||||||
0% | Class is less than half full | ||||||
UNSW Sydney NSW 2052, Australia Telephone: (within Aust.) 02 9385 1000, (International) +61 2 9385 1000 CRICOS Provider Code 00098G ABN: 57 195 873 179 Authorised by Vice-President and Deputy Vice-Chancellor (Academic) Privacy Policy Copyright & Disclaimer Accessibility |